TITLE

Extended-duration transdermal nicotine therapy was more effective than standard-duration therapy for smoking cessation

AUTHOR(S)
Lancaster, Tim; Stead, Lindsay
PUB. DATE
April 2010
SOURCE
ACP Journal Club;4/20/2010, Vol. 152 Issue 4, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on a study undertaken to find if extended-duration transdermal nicotine therapy is more effective than standard-duration therapy for smoking cessation. 573 adults participated in the randomized controlled trial. The study found that extended-duration transdermal nicotine therapy is more effective. Also charts and discussion of the result are presented.
ACCESSION #
50294726

 

Related Articles

  • A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. Berlin, Ivan; Hunneyball, Ian; Greiling, Doris; Jones, Stephen; Fuder, Hermann; Stahl, Hans-Detlev // Psychopharmacology;Sep2012, Vol. 223 Issue 1, p89 

    Rationale: Monoamine oxidase B (MAO-B) activity is reduced in smokers. A MAO-B inhibitor alone or co-administered with nicotine may mimic the effects of smoking and be a candidate drug for smoking cessation. Objective: This study aims to determine the efficacy and safety of EVT302, a selective...

  • Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence. Marteau, Theresa M; Munafò, Marcus R; Aveyard, Paul; Hill, Chloe; Whitwell, Sophia; Willis, Thomas A; Crockett, Rachel A; Hollands, Gareth J; Johnstone, Elaine C; Wright, Alison J; Prevost, A Toby; Armstrong, David; Sutton, Stephen; Kinmonth, Ann Louise // BMC Public Health;2010, Vol. 10, p680 

    Background: The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement...

  • Partner Support for Smoking Cessation During Pregnancy: A Systematic Review. Hemsing, Natalie; Greaves, Lorraine; O’Leary, Renée; Chan, Katharine; Okoli, Chizimuzo // Nicotine & Tobacco Research;Jul2012, Vol. 14 Issue 7, p767 

    Introduction: Pregnancy is a key time to leverage receptivity to smoking reduction or cessation in both pregnant women and their partners. A partner’s smoking status and support for the pregnant/postpartum woman’s efforts to reduce or quit smoking may impact her smoking behavior....

  • Quitters or not, patients still like nicotine patches. Starr, Cynthia // Drug Topics;11/22/93, Vol. 137 Issue 22, p24 

    Presents a study of what patients think of nicotine patches, the process they go through to procure these and what they learned from health professionals involved in their care. Users who are satisfied and who would use the product again if additional treatment were needed; Support from...

  • Effectiveness of Over-the-Counter Nicotine Replacement Therapy: A Qualitative Review of Nonrandomized Trials. Hughes, John R.; Peters, Erica N.; Naud, Shelly // Nicotine & Tobacco Research;Jul2011, Vol. 13 Issue 7, p512 

    Aim: Randomized trials conducted in over-the-counter (OTC) settings have shown that nicotine replacement therapy (NRT) is effective. This paper reviews nonrandomized tests of the effectiveness of OTC NRT. Methods: Literature search via computer and other methods located (a) retrospective cohort...

  • COST-EFFECTIVENESS OF THE NICOTINE PATCH. Stevermer, James // Journal of Family Practice;Aug1996, Vol. 43 Issue 2, p125 

    The article discusses research being done on the cost-effectiveness of the nicotine patch as an adjunct to smoking cessation counseling. It references a study by K. Fiscella and P. Franks, published in a 1996 issue of the "Journal of the American Medical Association." The investigators...

  • Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. Rose, Jed E.; Herskovic, Joseph E.; Behm, Frederique M.; Westman, Eric C. // Nicotine & Tobacco Research;Sep2009, Vol. 11 Issue 9, p1067 

    Introduction: Previous studies have reported that smoking abstinence rates are increased when nicotine skin patch treatment is initiated prior to the target quit smoking date, as compared with conventional treatment beginning on the quit date. We hypothesized that smoking in the presence of...

  • Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open- label trial. Aubin, H-J.; Bobak, A.; Button, J. R.; Oncken, C.; Billing Jr, C. B.; Gong, J.; Williams, K. E.; Reeves, K. R. // Thorax;Aug2008, Vol. 63 Issue 8, p717 

    Background: Varenicline, a new treatment for smoking cessation, has demonstrated significantly greater efficacy over placebo and sustained release bupropion (bupropion SA). A study was undertaken to compare a 12-week standard regimen of varenicline with a 10-week standard regimen of transdermal...

  • Adherence to nicotine replacement therapy among pregnant smokers. Fish, Laura J.; Peterson, Bercedis L.; Brouwer Namenek, Rebecca J.; Lyna, Pauline; Oncken, Cheryl A.; Swamy, Geeta K.; Myers, Evan R.; Pletsch, Pamela K.; Pollak, Kathryn I. // Nicotine & Tobacco Research;May2009, Vol. 11 Issue 5, p514 

    Introduction:: This secondary analysis examined the association between adherence to nicotine replacement therapy (NRT) and smoking cessation among pregnant smokers enrolled in Baby Steps, an open-label randomized controlled trial testing cognitive-behavioral therapy (CBT) versus CBT plus NRT.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics